Review Article
The Role of Oxidative Stress and Antioxidants in Diabetic Wound Healing

Liling Deng, Chenzhen Du, Peiyang Song, Tianyi Chen, Shunli Rui, David G. Armstrong, and Wuquan Deng

1Department of Endocrinology, Multidisciplinary Diabetic Foot Medical Center, Chongqing Emergency Medical Center, Chongqing University Central Hospital, Chongqing 400014, China
2Department of Surgery, Keck School of Medicine of the University of Southern California, CA, USA

Correspondence should be addressed to Wuquan Deng; wuquandeng@cqu.edu.cn

Received 12 October 2020; Accepted 29 December 2020; Published 8 February 2021

Academic Editor: Alin Ciobica

Copyright © 2021 Liling Deng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Foot ulcers are one of the most common and severe complications of diabetes mellitus with significant resultant morbidity and mortality. Multiple factors impair wound healing including skin injury, diabetic neuropathy, ischemia, infection, inadequate glycemic control, poor nutritional status, and severe morbidity. It is currently believed that oxidative stress plays a vital role in diabetic wound healing. An imbalance of free radicals and antioxidants in the body results in overproduction of reactive oxygen species which lead to cell, tissue damage, and delayed wound healing. Therefore, decreasing ROS levels through antioxidative systems may reduce oxidative stress-induced damage to improve healing. In this context, we provide an update on the role of oxidative stress and antioxidants in diabetic wound healing through following four perspectives. We then discuss several therapeutic strategies especially dietary bioactive compounds by targeting oxidative stress to improve wounds healing.

1. Introduction

Diabetes mellitus (DM) and its complications are increasingly prevalent worldwide with a serious burden on patients and health care systems [1]. Diabetic foot ulcers have a substantial impact on disability, morbidity, and mortality. The mechanism of diabetic wound chronicity has not been well understood. It is currently believed that oxidative stress plays a vital role in the occurrence and development of diabetic wound [2, 3]. Oxidative stress is caused by overproduction of reactive oxygen species and insufficient antioxidant systems. However, the process of oxidative stress in wound development and healing remains unclear. This review will further develop the discussion on how oxidative stress may affect diabetic wound healing in terms of skin injury, neuropathy, arterial disease, and infection. Furthermore, the plausible role of antioxidants including plant bioactive compounds on promoting wound healing will be addressed in order to explore novel approaches and strategies for promotion of diabetic wound healing.

2. Oxidative Stress State in the Development and Healing of Diabetic Wound

Reactive oxygen species (ROS) are crucial regulators of several phases of wound healing. Indeed, low levels of ROS are required for the fight against external damage [4]. However, excessive oxidative stress on tissues and the decrease of antioxidant ability results in redox imbalance, which is a major cause of nonhealing diabetic wounds [5]. Clinical studies investigated that nonhealing diabetic wounds are infiltrated by the highly oxidizing environment, which is associated with hyperglycemia and tissue hypoxia, that leads to delayed wound repair. People with long-term type 2 diabetes have significant reductions in the antioxidant enzyme activity [6]. Oxidative stress may influence diabetic wound healing through skin injury, neuropathy, ischemic lesion, and topical infection (Figure 1).

2.1. Diabetic Skin Injury. The repair process of diabetic skin injury includes the temporally overlapping stages of coagulation, inflammation, migration-proliferation, and
remodeling [7]. While the molecular mechanisms underlying such defects have not yet been clarified, some have reported that a hyperglycemic state directly affects the keratinocyte and fibroblast activity inducing changes in protein synthesis, proliferation, and migration, reduced antimicrobial peptide expression, and increased oxidative stress. These myriad changes may result in the injury of the skin barrier function making the skin susceptible to damage and infection [8–11].

A balanced redox state is likely critical for prompt healing. Diabetic skin appears to be infiltrated with more inflammatory cells, edema, and less granulation tissue formation than the normal skin, suggesting a deterioration in diabetic ulcer healing reserve [2, 7]. Additionally, the periwound and central wound tissue in people with diabetes appears to also be more likely to be prone to excessive oxidative stress and damage, which results in poor healing [12, 13]. Kim et al. suggested that both high oxidative stress levels and bacteria set the wound up for chronic wound development [14].

Experiments that have evaluated hypoxia and oxidative stress suggest that they may lead to the downregulation of miRNA biogenesis genes in cultured fibroblasts [15]. Recent efforts have indicated the levels of serum advanced glycation end product (AGE), and its epidermal receptors were elevated in diabetes [9, 16]. AGEs bind to receptors on the endothelial cell surface inducing the overproduction of ROS [17]. AGE in the diabetic wound microenvironment appears to impair wound contraction and prolongs the inflammatory response and appears to deleteriously damage extracellular matrix (ECM) proliferation [18]. Nrf2 is a key transcription factor involved in wound healing by regulating angiogenesis and antioxidant gene expression, which is impaired in diabetes [19, 20]. A recent study indicates that activation of Nrf2 signaling significantly increased TGF-β1 and reduced MMP9 in keratinocytes in diabetic wound healing [12]. Another study reported that SIRT1 (silent mating information regulation 2 homolog) activation could protect vascular endothelial cells from oxidative stress damage to improve angiogenesis in wounds to accelerate wound healing in diabetic mice, and this effect may be through the AKT-Nrf2 pathway [21]. Sirtuins are class III histone deacetylase enzymes which are evolutionarily conserved and possess NAD+ dependent deacetylase activity. Sirtuin 3 (SIRT3) is a protein deacetylase located in the mitochondria. It serves to regulate the mitochondrial function, which is involved in regulating cellular redox status, mitochondrial energetics, biogenesis, dynamics, and apoptosis. Recent work has demonstrated that the lack of SIRT3 reduced blood supply, inhibited vascular endothelial growth factor (VEGF) expression, promoted superoxide production, impaired total antioxidant capacity, and consequently resulted in delayed skin wound healing in diabetic mice [22]. Therefore, sirtuins may be a new therapeutic target to improve diabetic wound healing.

2.2. Diabetic Neuropathy. At least half of the people with diabetes will develop clinically significant peripheral neuropathy [23–25]. Sensory nerve dysfunction leads to the loss or weakening of skin protection. Motor neuropathy, which increases plantar pressure that directly destroys the tissue, causes plantar capillary occlusion, local tissue ischemia, and destruction [26]. The autonomic neuropathy of sweat glands in people with diabetes leads to reduced skin sweating, abnormal temperature regulation, and dry and chapped skin, which in turn damages the integrity of the skin, leading to a reduced barrier to infection. It also leads to perturbations in the skin blood flow and microcirculatory disorders such as loss of peripheral sympathetic nerve innervation and tension, leading to vasomotor dysfunction and abnormal arteriovenous shunting. As a result, the abnormal blood flow distribution and nutritional capillary ischemia could occur.

Figure 1: The role of oxidative stress in development and chronicity of diabetic wound.
It has been well demonstrated that hyperglycemia is a critical mechanism in the induction of oxidative stress. Increased oxidative stress appears to deleteriously affect blood supply, structure, and metabolism of the peripheral nerve [26] that leads to extensive deterioration to the all aspects of the peripheral nervous system including Schwann cells, myelinated axons, and sensory neurons located in the dorsal root ganglia [27]. Meanwhile, insufficient ATP supplies could lose the ability to transport axons, as axons were rich in mitochondria, providing direct nerve energy supply, thereby further promoting axonal injury, causing diabetic neuropathy. The loss of ability of detoxify the excess oxidative stress with insufficient ATP supplies led the axons oxidative stress damage in hyperglycemia, which precipitated axonal degeneration or apoptosis [28]. Studies have suggested that multiple biochemical pathways are deleteriously affected by oxidative stress (Figure 2).

2.2.1. Activated Polyol Pathway. The polyol pathway mainly includes the conversion of glucose to sorbitol by aldose reductase (AR) and the conversion of sorbitol to fructose by sorbitol dehydrogenase. In patients with diabetes, elevated intracellular levels of glucose cause the affinity of AR for glucose to also increase. This then leads to the increased production of sorbitol. Subsequent accumulation of sorbitol reduces the activity of Na+K+-ATPase which reduces the physiological reserve of nerve cells and commensurate reduction of nerve conduction velocity. It is also understood that the hyperglycemia-induced polyol pathway leads to increased oxidative stress because of depletion of NADPH, which is derived from the pentose phosphate pathway that generates GSH from glutathione. Meanwhile, excess fructose, as a product in metabolism, accelerates glycation and further consumption of NADPH to aggravate intracellular oxidative stress [29]. It has been confirmed in diabetic mice with high expression of aldose reductase. Diabetic mouse models indicate that sorbitol accumulates significantly in the sciatic nerve of diabetic AR+/+ mice. Traces of oxidative stress and DNA damage in the sciatic nerve were additionally observed [30]. Until now, aldose reductase inhibitors have been used to inhibit oxidative stress through the polyol pathway [31]. This may be beneficial for improving diabetic ulcer with concomitant neuropathy.
2.2.2. Activated Hexosamine Pathway. In an environment characterized by hyperglycemia, fructose-6 phosphate, a metabolic intermediate of glycolysis, is shifted from the glycolytic pathway to the hexosamine pathway and then converted to uridine diphosphate N-acetylglucosamine (UDP-GlcNAc). Subsequently, UDP-GlcNAc attaches to the serine and threonine residues of transcription factors [32]. Studies have reported activation of the hexosamine pathway leading to the impaired nerve function. In addition, the hexosamine pathway can promote the expression of cytokines such as TGF-α and TGF-β1 [33, 34].

Hyperglycemia activates the hexosamine pathway that eventually results in increasing of transcription factor Sp1, which is promoting the overexpression of TGF-β1 and plasminogen activator inhibitor-1 (PAI-1) in arterial endothelial cells [35, 36]. In addition, hyperglycemia induces the hexosamine pathway, and NF-κB signaling increases the expression of thrombospondin 2 (TSP2). TSP2 is a critical matricellular protein in injury responses. This appears to delay diabetic wound healing [37].

2.2.3. Activated AGE Pathway. In DM, nonenzymatic glycosylation of glucose can chemically interact with amino acids, lipids, and nucleic acids, which lead to the formation of reversible early glycosylation products. After chemical reconstitution irreversible AGEs subsequently form, AGE receptors exist in a variety of cell types such as vascular endothelial, vascular smooth cells, and others. As AGEs combine with their receptors, ultimately, extracellular and intracellular structure and function are altered [38]. The formation of AGEs on ECM molecules can increase ECM production and tissue stiffness directly or indirectly through activation of TGF-β receptors to stimulate cell growth. A signaling cascade triggered by the binding of AGEs to its receptor on the endothelial cell surface leads to activation of NADPH oxidase and overproduction of ROS, p21, RAS, and MAPKs. NF-κB is a key target of AGE-RAGE signaling. Excess oxidative stress derived from the AGE-RAGE axis activates NF-κB and affects transcriptional activation of numerous cytokines and adhesion molecules including endothelin-1, ICAM-1, E-selectin, and tissue factor, many of which are closely linked to inflammation and diabetic angiopathy [17].

AGEs also reduce the bioavailability of endothelium NO and cause the overproduction of ROS [39, 40]. It has been suggested that the AGEs-RAGE axis contributes to microvascular and macrovascular complications of diabetes [41]. Thus, the process of the AGE pathway might induce neuropathy via impairing vasodilation, thickening capillary basement membrane, and endothelial hyperplasia.

In addition to the aforementioned effects, AGEs negatively impact diabetic ulcer healing by increasing apoptosis, decreasing the proliferation of fibroblasts, and reducing the activity of growth factors such as fibroblast growth factor [42]. Moreover, AGE-induced autophagy is associated with delayed cutaneous ulcer healing through stimulation of M1 polarized macrophage [43, 44].

2.2.4. Activated PKC Pathway. PKC is comprised of a group of serine/threonine protein kinases with important physiological functions affecting many cellular signaling transduction pathways [45]. There are several isoforms of PKC, which play a critical role in multiple biological systems. PKCα, βI, βII, and δ are main components of the peripheral nerve [46]. In the environment of hyperglycemia, overproduction of oxygen free radicals inhibits the activity of glyceraldehyde phosphate dehydrogenase (GAPD). This leads to increased conversion of dihydroxyacetone phosphate (DHAP) to diacylglycerol (DAG), which in turn activates the PKC pathway [47]. Activated PKC can mediate the production of oxygen free radicals, inhibiting the activity of NO, thus leading to damage of the endothelial function.

A diabetic mouse study paradoxically reported decreased PKC activity. The difference from the previously stated results was likely due to the reduced expression of membrane PKC-α translocated to the cytoplasm, while the expression of membrane PKC-βII increased [48]. Recent studies have reported improved neural function of diabetic rats with the administration of nonselective PKC isoform inhibitors or selective PKCβ inhibitors. In addition, the sustained increasing PKCδ of human fibroblasts of DM hindered wound healing and insulin signaling was observed, thereby PKCδ inhibition may be a novel approach for treating diabetic wounds [49]. In summary, the mechanism of the PKC pathway in diabetic complications remains unclear.

Recent experiments have suggested that benfotiamine, a lipid-soluble analogue of vitamin B1, might improve diabetic wound healing via preventing the activation of the hexosamine pathway and the AGE and PKC pathway [50]. Preclinical studies showed that stimulating Nrf2-mediated antioxidant in the local regenerative environment of diabetic wounds significantly improved the molecular and cellular composition of wound beds [51].

The process of OS is irreversible and exerts a memory effect on metabolism with the correction of hyperglycemia [52, 53]. It was well demonstrated that the duration and severity of hyperglycemia were associated with the occurrence and progression of diabetic neuropathy, and enhanced glucose control delayed the process of developing clinical neuropathy in type 1 diabetes mellitus [3, 34]. However, conclusions in type 2 diabetes mellitus remain elusive [3, 55]. Indeed, strict glucose control does appear to impair nerve conduction velocity and vibration threshold in type 2 diabetes mellitus. This might be because neurons are more prone to severe hypoglycemic episodes. With acute glucose fluctuations, the PKC pathway is activated while inflammatory factors and adhesion molecules were secreted [56, 57], which further results in endothelial dysfunction and oxidative stress of the peripheral nerve.

2.3. Diabetic Peripheral Artery Disease. The role of diabetic angiopathy is well described in diabetic wounds. Diabetic microangiopathy and macroangiopathy are the combined result of irreversible complex nonenzymatic glycation, elevated oxidative stress and inflammation, and endothelial dysfunction and hypercoagulability state [58].

Oxidative stress caused by activated biochemical pathways, such as the AGE/RAGE pathway, the polyol pathway, PKC activation, and the hexosamine pathway, results in...
production of inflammatory mediators, pericyte degeneration, thickening basement membrane, endothelial hyperplasia, NO reduction, impaired vasodilation, and increasing procoagulant biomarkers, such as IL-6, TNF-α, D-dimer, and PAI-1. All of these are in one way or another involved in the development of diabetic microangiopathy [59–62]. The alteration of the capillary or arteriolar vessel structure prevented the delivery of nutrients and activated white blood cells to specific tissues, increases the susceptibility and severity of infections, and accelerates the occurrence and progression of diabetic ulcer. In addition, microthromboembolism might be more prone to occur in terminal vessels of smaller diameter, which aggravates ischemia and hypoxia of the local tissue in diabetic wounds. SKQ1 as a mitochondria-targeted antioxidant increased the number of myofibroblasts, lowered the levels of neutrophils, and elevated macrophage infiltration; moreover, SKQ1 decreased lipid peroxidation levels without alteration of circulatory IL-6 and TNF levels. SKQ1 treatment also improved cell migration, thereby improving dermal wound healing of genetically diabetic mice [63].

The biochemical pathways participated in the development of diabetic macroangiopathy were as follows: AGEs-RAGE axis, polyol pathway, hexosamine pathway, PKC activation, overproduction of ROS, and chronic inflammation [64, 65]. In turn, atherosclerosis induced endothelial dysfunction and inflammation, and these processes are worsened in diabetes [59]. Moreover, recent evidences investigated that hypoglycemia may also play an vital role in vascular complications of diabetes [66]. Hyperglycemia or short-term glucose fluctuations induced OS and proatherogenic gene expression alteration which will be long-lasting later even in normal glycemic conditions [67]. As a result, the lumen of large vessels in diabetes narrow or abstract, and tissue ischemia deteriorated, which lead to a delay in diabetic wound closure.

2.4. Topical Infection. Patients with uncontrolled DM are more prone to skin infections such as fungal and bacterial infections. In turn, infections make the wound more prone to skin infections such as fungal and bacterial infections [74, 75]. Furthermore, with SGLT2 inhibitor therapy, the proinflammatory phenotype and glucotoxicity in experimental diabetic animals were reversed [75]. In addition, hyperglycemia-induced mitochondrial dysfunction was relieved by SGLT2i in hyperglycemic mouse aorta vascular cultures [76]. Therefore, SGLT2i may be beneficial to diabetic wounds for healing.

Dipeptidyl peptidase-4 (DPP-4) inhibitors can lower blood glucose and reduce cardiovascular risk in patients with type 2 diabetes mellitus. Previous studies indicated that DPP-4 exerts a preventive effect on oxidative stress via Nrf2 or other pathways. Therefore, DPP-4 may be a treatment option for patients with diabetic chronic wounds [77, 78].

Fenofibrate, along with a proper diet to fight against high cholesterol and triglyceride levels, has been indicated to simulate keratinocyte differentiation and improve the skin barrier in vivo [79]. It also ameliorated oxidative stress and blockade of Wnt/β-catenin signaling [80]. These findings provide insights into treatment for diabetic ulcers. Systemically, use of statins exerts a reduction on cholesterol and can stimulate angiogenesis. Recent researches have revealed that stains can improve wound healing process in diabetic mice [81–83]. These may be a considerable therapy for patients with diabetic chronic wounds in clinic.

3. Antioxidants in Diabetic Wound Healing

3.1. Antioxidant Effects of Antimetabolism Imbalance Drugs on Wound Healing. Metformin is a classic therapy for DM. Recent literatures have reported that metformin improved angiogenic functions of endothelial and endothelial progenitor cells by activating the NOS pathway, and it is effective in the treatment of skin wounds in diabetic mice [72, 73].

SGLT2 inhibitors, as a novel glucose-lowering approach, grow evidence suggesting that it can lower the mRNA expression of TNF-α, IL-6 and MCP-1, and infiltration of inflammatory cells in the plaque and adipose tissue to improve inflammation and endothelial function, which seem to be involved in the alleviation of atherosclerosis by empagliflozin [74, 75]. Furthermore, with SGLT2 inhibitor therapy, the proinflammatory phenotype and glucotoxicity in experimental diabetic animals were reversed [75]. In addition, hyperglycemia-induced mitochondrial dysfunction was relieved by SGLT2i in hyperglycemic mouse aorta vascular cultures [76]. Therefore, SGLT2i may be beneficial to diabetic wounds for healing.

Dipeptidyl peptidase-4 (DPP-4) inhibitors can lower blood glucose and reduce cardiovascular risk in patients with type 2 diabetes mellitus. Previous studies indicated that DPP-4 exerts a preventive effect on oxidative stress via Nrf2 or other pathways. Therefore, DDP-4 may be a treatment option for patients with diabetic chronic wounds [77, 78].

Coenzyme Q10, an endogenous synthesized lipid and a vitamin-like substance primarily present in the mitochondria, ameliorates oxidant stress and apoptosis [86]. CoQ10 is an electron transport in the mitochondrial respiratory chain, consequently increasing energy generation of ATP and enhancing the mitochondrial antioxidant activity [87]. Aldose reductase inhibitors are used to inhibit oxidative stress by the polyol pathway [31], and it may be beneficial for improving diabetic ulcer with neuropathy.

3.3. Antioxidant Effects of Drugs for Diabetic Angiopathies on Wound Healing. Cilostazol, a phosphodiesterase type 3 inhibitor, has been suggested to be involved in the procedure of antiatherosclerosis with antiplatelet and vasodilatory effects. A study on diabetic mice indicated that cilostazol significantly reduced RAGE, ROS, NF-κB signaling, downstream gene expressions, and cell functions induced by hyperglycemia in VSMCs [88]. Low molecular-weight heparin ameliorates chronic diabetic wound healing, possibly by increasing microcirculation of wound margin [89, 90], but it is still controversy [91]. Iloprost improved limb perfusion and may be an important therapy for diabetic ulcerative lesions with severe ischemia [92]. However, there are only sparse data and lack of high-quality randomized controlled studies to show efficacy in any of these three agents [93].
3.4. Antioxidant Effects of Drugs for Diabetic Skin on Wound Healing. The epidermal growth factor (EGF) administration was beneficial for the alleviation of oxidative stress to improve wound repair [94]. Biogenic AgNPs synthesized from Brevibacillus brevis KN8 could inhibit the overexpression of MMP-2 and MMP-9 in granulation tissues and accelerated wound healing in diabetic mice beyond the antimicrobial activity [95]. Sodium pentaborate pentahydrate (NaB) displayed great antimicrobial properties and improved proliferation, migration, and the expression of growth factor and gene expression in dermis, and studies on diabetic rats proved that NaB improve diabetic wound healing rate [96].

3.5. Antioxidant Effects of Drugs for Diabetic Infection on Wound Healing. Strict antimicrobial dressing should be performed in diabetic ulcers with infection [97]. The microbial culture can be used to guide antimicrobial therapy. Efficient antimicrobial treatment with daptomycin [98] exerted positive effects on wound healing at the molecular level, such as reducing the level of local IL-6 and MMP-9 and increasing TIMP-1 in the MRSA-infected diabetic wound.

3.6. Antioxidant Effects of Plant Ingredients on Wound Healing. Ferulic acid (FA) is a natural antioxidant derived from fruits and vegetables that inhibited lipid peroxidation and increased the expression of catalase, superoxide dismutase, glutathione, nitric oxide, and serum zinc and copper, probably improving the healing process in diabetic ulcer [99]. Besides, syringic acid treatment also promotes migration and proliferation to improve wound healing [100].

| Table 1: Antioxidants and their potential benefit in diabetic wound healing. |
| --- |
| Drugs | Observation | Mechanism | Reference |
| **Antimetabolism imbalance** | | | |
| Metformin | Improved angiogenic functions of ECs and EPCs | NO, AMPK/mTOR pathway | [72, 73] |
| SGLT2i | Improve inflammation and endothelial function | Lower mRNA expression of TNF-α, IL-6, and MCP-1 | [74–76] |
| DDP-4i | Antioxidative stress | Nrf2 pathway | [77, 78] |
| Fenofibates | Improve skin barrier | Wnt/β-catenin pathway | [79, 80] |
| Statins | Promote angiogenesis and lymphangiogenesis | PI3-kinase/Akt pathway | [81–83] |
| **Therapy for diabetic neuropathy** | | | |
| ALA | Antioxidative stress | Inhibition of NF-κB | [64, 84, 85] |
| Aldose reductase inhibitors | Antioxidative stress | Polyol pathway | [31] |
| Coenzyme Q10 | Ameliorates oxidant stress and apoptosis | Increasing energy generation of ATP | [86, 87] |
| **Therapy for diabetic angiopathies** | | | |
| Cilostazol | Antiatherosclerosis | | [88] |
| Low molecular-weight heparin | Increase microcirculation | Anticoagulation | [89–91] |
| Iloprost | Improve limb perfusion | | [92] |
| **Therapy for the diabetic skin** | | | |
| EGF | Antioxidative stress | | [94] |
| Biogenic AgNPs | Accelerate wound healing | Inhibit overexpression of MMP-2 and MMP-9, antimicrobial | [95] |
| NaB | Accelerate wound healing | Antimicrobial activity and improve proliferation | [96] |
| **Therapy for infection** | | | |
| Antibiotics | Fight against for infection | | [97, 98] |
| **Plant ingredients for OS** | | | |
| Ferulic acid | Antioxidative stress | Reduce MMP (2, 8, 9) and increase TIMP-1 and 2 | [99, 100] |
| Chlorogenic acid | Antioxidative stress | Elevate the level of reduced glutathione | [102] |
| **Potential antioxidants** | | | |
| The drug-loaded ROS-scavenging hydrogel | Accelerate wound healing | Decrease ROS level and upregulate M2 phenotype macrophages | [103] |
| Deferoxamine | Promote neovascularization and regeneration | Suppress OS and activate hypoxia-inducible factor-1 alpha ion | [104] |
| Propolis | | Increase GSH/GSSG) ratio | [108] |
| N-Acetyl cysteine (NAC) | Accelerate wound healing | Accelerate wound healing | [109, 110] |
The fusion protein decreased serum proinflammatory cytokines such as IL-6, TNF-α, expression of cyclooxygenase-2, and increased activities of antioxidant enzyme including superoxide dismutase, glutathione peroxidase, and catalase, and it also increased proangiogenic cytokines levels including VEGF, intercellular adhesion molecule, and expression of VEGF, FGF-2, p-ERK, and p-Akt protein in granulation in diabetic rats, which significantly accelerated the diabetic wound healing [101].

Animal study has indicated chlorogenic acid, a dietary antioxidant, that could accelerate wound healing, enhance hydroxyproline content, decrease malondialdehyde/nitric oxide, and elevate the level of reduced glutathione in wound bed [102]. However, a number of researches are needed to furtherly confirm these data.

3.7. Antioxidant Effects of Potential Antioxidants on Wound Healing. The drug-loaded ROS-scavenging hydrogel promotes wound closure by decreasing the ROS level and upregulating M2 phenotype macrophages around the wound. Moreover, such hydrogels formed in wound also increased the release of granulocyte macrophage colony-stimulating factor to fight against external bacteria and improve the wound closure [103].

The experiment has indicated that deferoxamine (DFO) could reduce oxidative stress and promote hypoxia-inducible factor-1 alpha activation to facilitate neovascularization and regeneration in chronic diabetic wounds. Dominik Duscher has demonstrated the treatment of DFO and the enhanced concept drug delivery system treatment eTDDS that markedly increased wound vascularity, dermal thickness, collagen deposition, and tensile strength, thereby accelerating wound healing. Therefore, DFO eTDDS may have the potential in treatment of diabetic wounds [104].

In addition, vitamins A, C, and E are antioxidants [105]; however, some literature has reported that high doses of vitamins possibly increase the mortality of cardiovascular events and risk of tumors such as lung and skin tumors [106, 107]. Propolis could increase the glutathione (GSH) and GSH/glutathione disulfide (GSSG) ratio, deplete TNF, and increased interleukin10 levels to reduce the wound area [108]. Antioxidant with N-acetyl cysteine (NAC) is known to improve endothelial cell function and angiogenesis, and Mohamed et.al reported that daily NAC use improved postamputation stump healing, perfusion, neovascularization, and reduced muscle fiber damage [109, 110] (Table 1).

Further research is needed to confirm or refute whether these therapies are beneficial to diabetic wound healing. In addition, melatonin, taurine, and acetyl L-carnitine have been reported to improve oxidative stress in diabetic wounds in the recent literatures. However, a number of randomized controlled studies are needed to confirm.

4. Conclusion

Wound healing is a complex, dynamic process. However, most diabetic wounds are difficult to heal. Multiple factors such as hyperglycemia, neuropathy, blood supply, matrix turnover, wound contraction, and the microbiome play a role in the complex symphony of diabetic wound healing. Oxidative stress regulates wound healing through several related signal pathways. It therefore stands to reason that active control of ROS levels through antioxidants and antioxidative enzyme systems may reduce oxidative stress-induced damage to improve wound healing. Traditional systemic and topical medications could be beneficial for wound healing. Clinicians and scientists would do well to focus on development and testing of antioxidants to facilitate diabetic wound healing, thereby reducing the unnecessary burden of amputation, morbidity, and mortality in this population.

Conflicts of Interest

The authors declare no conflicts of interest.

Authors’ Contributions

WD conceived of and designed the study and revised the manuscript for important intellectual content. LD, PS, and TC performed the literature search. CD generated the figures and tables. WD and LD performed the background research. WD and DGA edited the manuscript. LD and WD drafted the manuscript. All authors have read and approved the content of the manuscript.

Acknowledgments

This research was funded by the Natural Science Foundation of Chongqing Municipal Science and Technology Bureau (cst2018cyjAX0335; cstc2020cjy-msxmX0298), the Fundamental Research Funds of Central Universities at Chongqing University (2019CDYGB020) awarded to Dr. Wuquan Deng, and also partially supported by the National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases (1R01124789-01A1) awarded to Dr. Armstrong DG.

References

[1] D. G. Armstrong, M. A. Swerdlow, A. A. Armstrong, M. S. Conte, W. V. Padula, and S. A. Bus, “Five year mortality and direct costs of care for people with diabetic foot complications are comparable to cancer,” Journal of Foot and Ankle Research, vol. 13, no. 1, p. 16, 2020.
[2] A. J. M. Boulton, D. G. Armstrong, M. J. Hardman et al., Diagnosis and management of diabetic foot infections, American Diabetes Association, Arlington, (VA), 2020.
[3] B. C. Callaghan, A. A. Little, E. L. Feldman, and R. A. C. Hughes, “Enhanced glucose control for preventing and treating diabetic neuropathy,” Cochrane Database of Systematic Reviews, vol. 6, article Cd007543, 2012.
[4] C. Dunnill, T. Patton, J. Brennan et al., “Reactive oxygen species (ROS) and wound healing: the functional role of ROS and emerging ROS-modulating technologies for augmentation of the healing process,” International Wound Journal, vol. 14, no. 1, pp. 89–96, 2017.
[5] M. C. Sanchez, S. Lancel, E. Boulanger, and R. Neviere, “Targeting oxidative stress and mitochondrial dysfunction in the...
treatment of impaired wound healing: a systematic review,” Antioxidants, vol. 7, no. 8, p. 98, 2018.
[6] J. Dworzanski, M. Strycharz-Dudziak, E. Kliszczewska et al., “Glutathione peroxidase (GPx) and superoxide dismutase (SOD) activity in patients with diabetes mellitus type 2 infected with Epstein-Barr virus,” PLoS One, vol. 15, no. 3, article e0230574, 2020.
[7] D. G. Armstrong and G. C. Gurtner, “A histologically hostile environment made more hospitable?,” Nature Reviews Endocrinology, vol. 14, no. 9, pp. 511–512, 2018.
[8] A. L. Lima, T. Illing, S. Schliemann, and P. Elsner, “Cutaneous manifestations of diabetes mellitus: a review,” American Journal of Clinical Dermatology, vol. 18, no. 4, pp. 541–553, 2017.
[9] J. H. Kim, N. Y. Yoon, D. H. Kim et al., “NRF2 signaling normalizes the regenerative niche, Diabetes Research, vol. 2017, article 4826724, 15 pages, 2017.
[10] J. H. Kim, B. Yang, A. Tedesco et al., “NRF2 in diabetic wound healing,” Experimental Dermatology, vol. 18, no. 4, pp. 541–553, 2017.
[11] J. Dworzanski, M. Strycharz-Dudziak, E. Kliszczewska et al., “High levels of oxidative stress and increased interleukin-8 secretion from keratinocytes: new insights into impaired diabetic wound healing,” Journal of Dermatology, vol. 9, no. 1, p. 19318, 2019.
[12] D. C. Rosenberger, V. Blechschmidt, H. Timmerman, A. Wolff, and R.-D. Treede, “Challenges of neuropathic pain: focus on diabetic neuropathy,” Journal of Neurotransmission, vol. 127, pp. 589–624, 2020.
[13] P. Fernyhough and J. McGavock, “Mechanisms of disease,” Handbook of clinical neurology, vol. 126, pp. 353–377, 2014.
[14] J. H. Kim, N. Y. Yoon, D. H. Kim et al., “NRF2 signaling normalizes the regenerative niche, Diabetes Research, vol. 2017, article 4826724, 15 pages, 2017.
[15] D. G. Armstrong, A. J. M. Boulton, and S. A. Bus, “Diabetic foot ulcers and their recurrence,” The New England Journal of Medicine, vol. 376, no. 24, pp. 2367–2375, 2017.
[16] D. G. Armstrong, “The 10-g monofilament: the diagnostic divining rod for the diabetic foot?,” Diabetes Care, vol. 23, no. 7, p. 887, 2000.
[17] J. H. Kim, B. Yang, A. Tedesco et al., “Advanced glycaemic condition impairs skin barrier by accelerating skin aging process,” Experimental Dermatology, vol. 20, no. 12, pp. 969–974, 2011.
[18] T. A. M. Andrade, D. S. Masson-Meyers, G. F. Caetano et al., “Skin changes in streptozotocin-induced diabetic rats,” Biochemical and Biophysical Research Communications, vol. 490, no. 4, pp. 1154–1161, 2017.
[19] J. H. Kim, N. Y. Yoon, D. H. Kim et al., “NRF2 signaling normalizes the regenerative niche, Diabetes Research, vol. 2017, article 4826724, 15 pages, 2017.
[20] D. G. Armstrong, L. A. Lavery, and L. B. Harkless, “Who is at risk for diabetic foot ulceration?,” Clinics in Podiatric Medicine and Surgery, vol. 15, no. 1, pp. 11–19, 1998.
[21] I. G. Obrosova, “Update on the pathogenesis of diabetic neuropathy,” Current Diabetes Reports, vol. 3, no. 6, pp. 439–445, 2003.
[22] P. Fernyhough and J. McGavock, “Mechanisms of disease,” Handbook of clinical neurology, vol. 126, pp. 353–377, 2014.
[23] D. G. Armstrong, A. J. M. Boulton, and S. A. Bus, “Diabetic foot ulcers and their recurrence,” The New England Journal of Medicine, vol. 376, no. 24, pp. 2367–2375, 2017.
[24] D. G. Armstrong, “The 10-g monofilament: the diagnostic divining rod for the diabetic foot?,” Diabetes Care, vol. 23, no. 7, p. 887, 2000.
[25] D. G. Armstrong, L. A. Lavery, and L. B. Harkless, “Who is at risk for diabetic foot ulceration?,” Clinics in Podiatric Medicine and Surgery, vol. 15, no. 1, pp. 11–19, 1998.
[26] D. C. Rosenberger, V. Blechschmidt, H. Timmerman, A. Wolff, and R.-D. Treede, “Challenges of neuropathic pain: focus on diabetic neuropathy,” Journal of Neurotransmission, vol. 127, pp. 589–624, 2020.
[27] P. Fernyhough and J. McGavock, “Mechanisms of disease,” Handbook of clinical neurology, vol. 126, pp. 353–377, 2014.
[28] D. G. Armstrong, L. A. Lavery, and L. B. Harkless, “Who is at risk for diabetic foot ulceration?,” Clinics in Podiatric Medicine and Surgery, vol. 15, no. 1, pp. 11–19, 1998.
[29] D. C. Rosenberger, V. Blechschmidt, H. Timmerman, A. Wolff, and R.-D. Treede, “Challenges of neuropathic pain: focus on diabetic neuropathy,” Journal of Neurotransmission, vol. 127, pp. 589–624, 2020.
[30] D. G. Armstrong, L. A. Lavery, and L. B. Harkless, “Who is at risk for diabetic foot ulceration?,” Clinics in Podiatric Medicine and Surgery, vol. 15, no. 1, pp. 11–19, 1998.
[31] D. C. Rosenberger, V. Blechschmidt, H. Timmerman, A. Wolff, and R.-D. Treede, “Challenges of neuropathic pain: focus on diabetic neuropathy,” Journal of Neurotransmission, vol. 127, pp. 589–624, 2020.
[32] P. Fernyhough and J. McGavock, “Mechanisms of disease,” Handbook of clinical neurology, vol. 126, pp. 353–377, 2014.
[33] D. G. Armstrong, L. A. Lavery, and L. B. Harkless, “Who is at risk for diabetic foot ulceration?,” Clinics in Podiatric Medicine and Surgery, vol. 15, no. 1, pp. 11–19, 1998.
[34] D. C. Rosenberger, V. Blechschmidt, H. Timmerman, A. Wolff, and R.-D. Treede, “Challenges of neuropathic pain: focus on diabetic neuropathy,” Journal of Neurotransmission, vol. 127, pp. 589–624, 2020.
[35] P. Fernyhough and J. McGavock, “Mechanisms of disease,” Handbook of clinical neurology, vol. 126, pp. 353–377, 2014.
Y.-Q. Chen, M. Su, R. R. Walia, Q. Hao, J. W. Covington, and D. E. Vaughan, “Sp1 sites mediate activation of the plasminogen activator inhibitor-1 promoter by glucose in vascular smooth muscle cells,” *Journal of Biological Chemistry*, vol. 273, pp. 8225–8231, 1998.

B. Kunkemöeller, T. Bancroft, H. Xing et al., “Elevated thrombospondin 2 contributes to delayed wound healing in diabetes,” *Diabetes*, vol. 68, no. 10, pp. 2016–2023, 2019.

C. Y. Chen, A. M. Abell, Y. S. Moon, and K. H. Kim, “An advanced glycation end product (AGE)-receptor for AGES (RAGE) axis restores adipogenic potential of senescent preadipocytes through modulation of p53 protein function,” *The Journal of biological chemistry*, vol. 287, no. 53, pp. 44498–44507, 2012.

G. D. Frank, S. Eguchi, and E. D. Motley, “The role of reactive oxygen species in insulin signaling in the vasculature,” *Antioxidants & redox signaling*, vol. 7, no. 7-8, pp. 1053–1061, 2005.

Y. Duraisamy, M. Slevin, N. Smith et al., “Effect of glycation on basic fibroblast growth factor induced angiogenesis and activation of associated signal transduction pathways in vascular endothelial cells: possible relevance to wound healing in diabetes,” *Angiogenesis*, vol. 4, no. 4, pp. 277–288, 2001.

R. Kang, D. Tang, M. T. Lotze, and H. J. Zeh 3rd., “RAGE regulates autophagy and apoptosis following oxidative injury,” *Autophagy*, vol. 7, pp. 442–444, 2014.

Y. Guo, C. Lin, P. Xu et al., “AGEs induced autophagy impairs cutaneous wound healing via stimulating macrophage polarization to M1 in diabetes,” *Scientific Reports*, vol. 6, no. 1, article 36416, 2016.

M. Freeley, D. Kelleher, and A. Long, “Regulation of protein kinase C function by phosphorylation on conserved and non-conserved sites,” *Cellular signalling*, vol. 23, no. 5, pp. 753–762, 2011.

C. P. Tseng and A. K. Verma, “Functional expression and characterization of the mouse epitone tag-protein kinase C isoforms, alpha, beta I, beta II, gamma, delta and epsilon,” *Gene*, vol. 169, no. 2, pp. 287–288, 1996.

M. Brownlee, “Biochemistry and molecular cell biology of diabetic complications,” *Nature*, vol. 414, no. 6865, pp. 813–820, 2001.

K. Uehara, S.-I. Yamagishi, S. Otsuki, S. Chin, and S. Yagihashi, “Effects of polyol pathway hyperactivity on protein kinase C activity, nociceptive peptide expression, and neuronal structure in dorsal root ganglia in diabetic mice,” *Diabetes*, vol. 53, no. 12, pp. 3239–3247, 2004.

M. Khamaisi, S. Katagiri, H. Keenan et al., “PKCγ inhibition normalizes the wound-healing capacity of diabetic human fibroblasts,” *The Journal of clinical investigation*, vol. 126, no. 3, pp. 837–853, 2016.

A. Stirban, M. Negrean, B. Stratmann et al., “Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes,” *Diabetes Care*, vol. 29, no. 9, pp. 2064–2071, 2006.

P. S. Rabbani, T. Ellison, B. Waqas et al., “Targeted Nrf2 activation therapy with RTA 408 enhances regenerative capacity of diabetic wounds,” *Diabetes Research and Clinical Practice*, vol. 139, pp. 11–23, 2018.

A. Ceriello, S. Kumar, L. Piconi, K. Esposito, and D. Giugliano, “Simultaneous control of hyperglycemia and oxidative stress normalizes endothelial function in type 1 diabetes,” *Diabetes Care*, vol. 30, no. 3, pp. 649–654, 2007.

A. Ceriello, M. A. Ihnat, and J. E. Thorpe, “Clinical review 2: the “metabolic memory”: is more than just tight glucose control necessary to prevent diabetic complications?,” *The Journal of Clinical Endocrinology and Metabolism*, vol. 94, no. 2, pp. 410–415, 2009.

B. Fullerton, J. Keitler, M. Seitz, K. Horvath, A. Berghold, and A. Siebenhofer, “Intense glucose control versus conventional glucose control for type 1 diabetes mellitus,” *Cochrane Database of Systematic Reviews*, vol. 2014, article Cd009122, 2014.

K. M. Pantalone, A. D. Misra-Hebert, T. M. Hobbs et al., “Effect of glycemic control on the diabetes complications severity index score and development of complications in people with newly diagnosed type 2 diabetes,” *Journal of Diabetes*, vol. 10, no. 3, pp. 192–199, 2018.

L. Monnier, E. Mas, C. Ginet et al., “Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes,” *Journal of the American Medical Association*, vol. 295, no. 14, pp. 1681–1687, 2006.

A. Ceriello, K. Esposito, L. Piconi et al., “Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients,” *Diabetes*, vol. 57, no. 5, pp. 1349–1354, 2008.

R. B. Goldberg, “Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications,” *The Journal of Clinical Endocrinology and Metabolism*, vol. 94, no. 9, pp. 3171–3182, 2009.

G. Balasubramanian, P. Vas, N. Chockalingam, and R. Naemi, “A Synoptic Overview of Neurovascular Interactions in the Foot,” *Frontiers in Endocrinology*, vol. 11, 2020.

B. T. Ngo, K. D. Hayes, D. J. DiMiao, S. K. Srinivasan, C. J. Huerter, and M. S. Rendell, “Manifestations of cutaneous diabetic microangiopathy,” *American Journal of Clinical Dermatology*, vol. 6, no. 4, pp. 225–237, 2005.

C. P. Dominguetti, L. M. Sant’Ana Dusse, M. das Graças Cavalcio, L. P. de Sousa, K. B. Gomes, and A. P. Fernandes, “Diabetes mellitus: the linkage between oxidative stress, inflammation, hypercoagulability and vascular complications,” *Journal of Diabetes and its Complications*, vol. 30, no. 4, pp. 738–745, 2016.

F. Semeraro, F. Morescalchi, A. Cancarini, A. Russo, S. Rezzola, and C. Costagliola, “Diabetic retinopathy, a vascular and inflammatory disease: therapeutical implications,” *Diabetes & Metabolism*, vol. 45, no. 6, pp. 517–527, 2019.

I. A. Demyanenko, V. V. Zakharova, O. P. Ilivinskaya et al., “Mitochondria-targeted antioxidant SkQ1 improves dermal wound healing in genetically diabetic mice,” *Oxidative Medicine and Cellular Longevity*, vol. 2017, Article ID 6408278, 10 pages, 2017.
G. Daeschlein, P. Hinz, T. Kiefer, and M. Jünger, “Mechanism of development of atherosclerosis and cardiovascular disease in diabetes mellitus,” *Journal of Atherosclerosis and Thrombosis*, vol. 25, no. 1, pp. 27–39, 2018.

M. Hanefeld, E. Duetting, and P. Bramlage, “Cardiac implications of hypoglycemia in patients with diabetes - a systematic review,” *Cardiovascular Diabetology*, vol. 12, no. 1, p. 135, 2013.

A. El-Osta, D. Brasacchio, D. Yao et al., “Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia,” *The Journal of Experimental Medicine*, vol. 205, no. 10, pp. 2409–2417, 2008.

G. Daeschlein, P. Hinz, T. Kiefer, and M. Jünger, “Role of the microbiome in chronic wounds,” *Der Hautarzt*, vol. 70, pp. 422–431, 2019.

A. Spichler, B. L. Hurwitz, D. G. Armstrong, and B. A. Lipsky, “Microbiology of diabetic foot infections: from Louis Pasteur to ‘crime scene investigation’,” *BMC Medicine*, vol. 13, no. 1, p. 2, 2015.

A. S. Moffarah, M. Al Mohajer, B. L. Hurwitz, and D. G. Armstrong, “Skin and soft tissue infections,” in *Diagnostic Microbiology of the Immunocompromised Host*, pp. 51–68, Wiley, 2016.

G. S. Watts, J. E. Thornton, K. Youens-Clark et al., “Identification and quantitation of clinically relevant microbes in patient samples: comparison of three k-mer based classifiers for speed, accuracy, and sensitivity,” *PLoS Computational Biology*, vol. 15, no. 11, article e1006863, 2019.

L. M. Shawky, E. A. El Bana, and A. A. Morsi, “Stem cells and metformin synergistically promote healing in experimentally induced cutaneous wound injury in diabetic rats,” *Folia Histochemica et Cytobiologica*, vol. 57, no. 3, pp. 127–138, 2019.

X. Han, Y. Tao, Y. Deng, J. Yu, Y. Sun, and G. Jiang, “Metformin accelerates wound healing in type 2 diabetic db/db mice,” *Molecular Medicine Reports*, vol. 16, no. 6, pp. 8691–8698, 2017.

J. H. Han, T. J. Oh, G. Lee et al., “The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE (-/-) mice fed a western diet,” *Diabetologia*, vol. 60, no. 2, pp. 364–376, 2017.

M. Oelze, S. Kröller-Schön, P. Welsch et al., “The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity,” *PLoS One*, vol. 9, article e112394, 2014.

V. K. Pulakazhi Venu, M. El-Daly, M. Saifeddine et al., “Minimizing hyperglycemia-induced vascular endothelial dysfunction by inhibiting endothelial sodium-glucose cotransporter 2 and attenuating oxidative stress: implications for treating individuals with type 2 diabetes,” *Canadian Journal of Diabetes*, vol. 43, no. 7, pp. 510–514, 2019.

S. H. Choi, S. Park, C. J. Oh, J. Leem, K. G. Park, and I. K. Lee, “Dipeptidyl peptidase-4 inhibition by gemigliptin prevents abnormal vascular remodeling via NF-E2-related factor 2 activation,” *Vascular Pharmacology*, vol. 73, pp. 11–19, 2015.

G. S. Watts, J. E. Thornton, K. Youens-Clark et al., “Identification and quantitation of clinically relevant microbes in patient samples: comparison of three k-mer based classifiers for speed, accuracy, and sensitivity,” *PLoS Computational Biology*, vol. 15, no. 11, article e1006863, 2019.

A. S. Moffarah, M. Al Mohajer, B. L. Hurwitz, and D. G. Armstrong, “Skin and soft tissue infections,” in *Diagnostic Microbiology of the Immunocompromised Host*, pp. 51–68, Wiley, 2016.

G. Daeschlein, P. Hinz, T. Kiefer, and M. Jünger, “Role of the microbiome in chronic wounds,” *Der Hautarzt*, vol. 70, pp. 422–431, 2019.

A. Spichler, B. L. Hurwitz, D. G. Armstrong, and B. A. Lipsky, “Microbiology of diabetic foot infections: from Louis Pasteur to ‘crime scene investigation’,” *BMC Medicine*, vol. 13, no. 1, p. 2, 2015.

A. S. Moffarah, M. Al Mohajer, B. L. Hurwitz, and D. G. Armstrong, “Skin and soft tissue infections,” in *Diagnostic Microbiology of the Immunocompromised Host*, pp. 51–68, Wiley, 2016.

G. S. Watts, J. E. Thornton, K. Youens-Clark et al., “Identification and quantitation of clinically relevant microbes in patient samples: comparison of three k-mer based classifiers for speed, accuracy, and sensitivity,” *PLoS Computational Biology*, vol. 15, no. 11, article e1006863, 2019.

L. M. Shawky, E. A. El Bana, and A. A. Morsi, “Stem cells and metformin synergistically promote healing in experimentally induced cutaneous wound injury in diabetic rats,” *Folia Histochemica et Cytobiologica*, vol. 57, no. 3, pp. 127–138, 2019.

X. Han, Y. Tao, Y. Deng, J. Yu, Y. Sun, and G. Jiang, “Metformin accelerates wound healing in type 2 diabetic db/db mice,” *Molecular Medicine Reports*, vol. 16, no. 6, pp. 8691–8698, 2017.

J. H. Han, T. J. Oh, G. Lee et al., “The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE (-/-) mice fed a western diet,” *Diabetologia*, vol. 60, no. 2, pp. 364–376, 2017.

M. Oelze, S. Kröller-Schön, P. Welsch et al., “The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity,” *PLoS One*, vol. 9, article e112394, 2014.

V. K. Pulakazhi Venu, M. El-Daly, M. Saifeddine et al., “Minimizing hyperglycemia-induced vascular endothelial dysfunction by inhibiting endothelial sodium-glucose cotransporter 2 and attenuating oxidative stress: implications for treating individuals with type 2 diabetes,” *Canadian Journal of Diabetes*, vol. 43, no. 7, pp. 510–514, 2019.

S. H. Choi, S. Park, C. J. Oh, J. Leem, K. G. Park, and I. K. Lee, “Dipeptidyl peptidase-4 inhibition by gemigliptin prevents abnormal vascular remodeling via NF-E2-related factor 2 activation,” *Vascular Pharmacology*, vol. 73, pp. 11–19, 2015.
peripheral arterial occlusive disease and foot ulcers,” *Chirurgia Italiana*, vol. 57, pp. 731–735, 2005.

[93] T. Elrayyah, A. Tsapas, G. Prutsky et al., “A systematic review and meta-analysis of adjunctive therapies in diabetic foot ulcers,” *Journal of Vascular Surgery*, vol. 63, 2016.

[94] A. G. Ojalvo, J. B. Acosta, Y. M. Mari et al., “Healing enhancement of diabetic wounds by locally infiltrated epidermal growth factor is associated with systemic oxidative stress reduction,” *International Wound Journal*, vol. 14, no. 1, pp. 214–225, 2017.

[95] N. Krishnan, B. Velramar, B. Ramatchandiran et al., “Effect of biogenic silver nanocubes on matrix metalloproteinases 2 and 9 expressions in hyperglycemic skin injury and its impact in early wound healing in streptozotocin-induced diabetic mice,” *Materials Science and Engineering: C*, vol. 91, pp. 146–152, 2018.

[96] S. Demirci, A. Doğan, S. Aydin, E. Ç. Dülger, and F. Şahin, “Boron promotes streptozotocin-induced diabetic wound healing: roles in cell proliferation and migration, growth factor expression, and inflammation,” *Molecular and Cellular Biochemistry*, vol. 417, no. 1-2, pp. 119–133, 2016.

[97] J. C. Dumville, B. A. Lipsky, C. Hoey, M. Cruciani, M. Fiscon, and J. Xia, “Topical antimicrobial agents for treating foot ulcers in people with diabetes,” *Cochrane Database of Systematic Review*, vol. 6, article Cd011038, 2017.

[98] A. Ambrosch, D. Halevy, B. Fwity, T. Brin, and R. Lobmann, “Effect of daptomycin on local interleukin-6, matrix metalloproteinase-9, and metallopeptidase inhibitor 1 in patients with MRSA-infected diabetic foot,” *The international journal of lower extremity wounds*, vol. 13, no. 1, pp. 12–16, 2014.

[99] M. M. Ghaisas, S. B. Kshirsagar, and R. S. Sahane, “Evaluation of wound healing activity of ferulic acid in diabetic rats,” *International Wound Journal*, vol. 11, no. 5, pp. 523–532, 2014.

[100] J. Ren, M. Yang, F. Xu, J. Chen, and S. Ma, “Acceleration of wound healing activity with syringic acid in streptozotocin induced diabetic rats,” *Life Sciences*, vol. 233, p. 116728, 2019.

[101] Q. Chen, W. Li, J. Wang, X. Qu, and G. Wang, “Lysozyme-antimicrobial peptide fusion protein promotes the diabetic wound size reduction in streptozotocin (STZ)-induced diabetic rats,” *Medical science monitor : international medical journal of experimental and clinical research*, vol. 24, pp. 8449–8458, 2018.

[102] D. Bagdas, B. C. Etoz, Z. Gul et al., “In vivo systemic chlorogenic acid therapy under diabetic conditions: wound healing effects and cytotoxicity/genotoxicity profile,” *Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association*, vol. 81, pp. 54–61, 2015.

[103] H. Zhao, J. Huang, Y. Li et al., “ROS-scavenging hydrogel to promote healing of bacteria infected diabetic wounds,” *Biomaterials*, vol. 258, p. 120286, 2020.

[104] D. Duscher, A. A. Trotsyuk, Z. N. Maan et al., “Optimization of transdermal deferroxamine leads to enhanced efficacy in healing skin wounds,” *Journal of Controlled Release*, vol. 308, pp. 232–239, 2019.

[105] A. F. M. Pessoa, J. C. Florim, H. G. Rodrigues et al., “Oral administration of antioxidants improves skin wound healing in diabetic mice,” *Wound Repair and Regeneration*, vol. 24, pp. 981–993, 2016.

[106] G. S. Omenn, G. E. Goodman, M. D. Thornquist et al., “Risk factors for lung cancer and for intervention effects in CARET, the Beta-carotene and retinol efficacy trial,” *JNCI: Journal of the National Cancer Institute*, vol. 88, no. 21, pp. 1550–1559, 1996.

[107] J. J. Challem, “Re: risk factors for lung cancer and for intervention effects in CARET, the Beta-carotene and retinol efficacy trial,” *Journal of the National Cancer Institute*, vol. 89, no. 4, pp. 325–326, 1997.

[108] V. Mujica, R. Orrego, R. Fuentalba, E. Leiva, and J. Zúñiga-Hernández, “Propolis as an adjuvant in the healing of human diabetic foot wounds receiving care in the diagnostic and treatment centre from the regional hospital of Talca,” *Journal Diabetes Research*, vol. 2019, article 2507578, 10 pages, 2019.

[109] M. A. Babizhayev, I. A. Strokov, V. V. Nosikov et al., “The role of oxidative stress in diabetic neuropathy: generation of free radical species in the glycation reaction and gene polymorphisms encoding antioxidant enzymes to genetic susceptibility to diabetic neuropathy in population of type I diabetic patients,” *Cell Biochemistry and Biophysics*, vol. 71, no. 3, pp. 1425–1443, 2015.

[110] M. A. Zayed, X. Wei, K. M. Park et al., “N-Acetylcysteine accelerates amputation stump healing in the setting of diabetes,” *FASEB Journal*, vol. 31, no. 6, pp. 2686–2695, 2017.